Table 3.

Factors associated with increase in acute care use 6 months before and after initiation of androgen receptor signaling inhibitors

Covariates	Odds ratio (95% CI)	p-value
Diabetes (Yes vs No)	1.22 (0.96–1.55)	0.10
Drug type (Abi vs Enza/Apa)	1.42 (1.07–1.88)	0.016*
Age (per year)	1.01 (1.00–1.03)	0.10
NCI comorbidity index (per unit)	1.54 (1.26–1.90)	<0.001**
Race (Black vs White)	0.83 (0.57–1.19)	0.31
Race (Other vs White)	1.01 (0.65–1.56)	0.98
Marital Status (Unmarried vs Married)	0.98 (0.77–1.24)	0.87
Region (Northern Plains vs East)	0.81 (0.57–1.15)	0.23
Region (Pacific Coast vs East)	1.05 (0.82–1.34)	0.70
Region (Southwest vs East)	1.05 (0.65–1.70)	0.85
SES (Non HS >10% vs <10%)	0.91 (0.73–1.13)	0.38

^*P<0.05,

^**P<0.01